The Central Government is preparing for the deployment of the vaccine for Covid-19 throughout the country. A test has been planned in Andhra Pradesh, Assam, Gujarat, Punjab considering the geographical locations. The detailed checklist has been prepared by the Union Ministry of Health and shared with the four states to guide them through the trial.
“To strengthen the capacity of our human resource for the introduction and deployment of the COVID-19 vaccine, detailed training modules have been developed for different categories of vaccine handlers and administrators, including medical officers, vaccinators, alternative vaccinators, vaccine handlers, cold chain, supervisors, data managers, ASHA coordinators and everyone else involved in the implementation process at different levels, “the government statement said.
Read also | The global push to reinvent capitalism
2,360 trainings carried out; more than 7,000 district students trained
2,360 participants were trained during the National Training of Trainers, which included state immunization officials, cold chain officials, IEC officials, development partners, etc. To date, the statewide trainings had been completed in all states / UT with the participation of more than 7000 apprentice-level districts, except Lakshadweep, which will take place soon (December 29). In cascade, 681 districts (49,604 fellows) have completed training of medical officers on operational guidelines. Vaccination team training was completed in 1,399 out of 17,831 planning blocks / units. Continue on the other blocks.
Strengthened national and state helpline
To facilitate the resolution of COVID-19 vaccination inquiries and inquiries related to the Co-WIN portal, the capacity of the national 1075 and state 104 helpline has also been strengthened to address inquiries beyond their routine support.
Trial for Vaccine Administration in 4 States Next Week
A test is planned in four states: Andhra Pradesh, Assam, Gujarat and Punjab. Each state will plan it in two districts and preferably in different (five) session type settings, eg district hospital, CHC / PHC, urban site, private health facility, rural outreach, etc. The COVID-19 vaccination process (except the vaccine) and verify the use of Co-WIN in the field setting, the links between planning, implementation and reporting mechanisms and identify challenges and guide the way forward before the actual implementation, including any improvements that may be required to the planned process. This will also provide hands-on experience for program managers at various levels. This two-day activity is planned for December 28 and 29, 2020 and will include activities from the necessary data entries in Co-WIN to the receipt and assignment of vaccines for the deployment of team members, mock sites of session with the test beneficiaries to inform and the evening meeting. This will also include testing for cold storage and transportation arrangements for the COVID19 vaccine, crowd management at the session sites with adequate physical distance.
Three priority population groups for the Covid-19 vaccine
The National Group of Experts on COVID-19 Vaccine Administration (NEGVAC) has recommended three prioritized population groups, including healthcare workers (TS) (approximately 1 crore), front-line workers (PDA) (approximately 2 crore) and the prioritized age group (approximately 27 crore).
Vaccine storage
Since vaccines are temperature sensitive and must be stored at a specific temperature, the current cold chain system consisting of 85,634 kits for the storage of the vaccine at approximately 28,947 cold chain points throughout the country will be used. for the management of the cold chain. The current cold chain is capable of storing an additional quantity of the Covid-19 vaccine necessary for the prioritized population of the first 3 crore, that is, healthcare workers and frontline workers.
6 candidate vaccines in various stages of clinical trial in India
The six candidate vaccines that are in various stages of the clinical trial are: Covishield, Covaxin, ZyCoV-D, Sputnik V, NVX-CoV2373 and a vaccine based on recombinant protein antigens, according to the Ministry of Health.
.